

Glucagon-Like Peptide 1 Market Outlook 2025-2034: Market Share, and Growth Analysis By Product (Trulicity, Ozempic, Victoza, Rybelsus, Other Types), By Route of Administration (Oral, Parenteral, Other Routes), By End-Users

<https://marketpublishers.com/r/GB8B963FC5F5EN.html>

Date: October 2025

Pages: 160

Price: US\$ 3,950.00 (Single User License)

ID: GB8B963FC5F5EN

Abstracts

The Glucagon-Like Peptide 1 Market is valued at USD 18.1 billion in 2025 and is projected to grow at a CAGR of 8.1% to reach USD 36.5 billion by 2034.

Glucagon-like Peptide 1 Market Overview

The Glucagon-like Peptide 1 (GLP-1) market has emerged as a vital segment within the diabetes and obesity treatment landscape, driven by increasing awareness and growing demand for innovative therapies. GLP-1 receptor agonists mimic natural hormones that stimulate insulin secretion and inhibit glucagon, offering an effective treatment option for Type 2 diabetes and, increasingly, for obesity management. With the rising global burden of metabolic disorders and the need for long-term glycemic control, pharmaceutical companies are intensifying research and development in GLP-1-based treatments. The market is witnessing robust expansion across North America, Europe, and parts of Asia-Pacific, with injectable and oral formulations steadily gaining traction among healthcare providers and patients. Increased regulatory approvals and strong clinical evidence supporting efficacy and cardiovascular benefits further reinforce GLP-1's position in treatment protocols. As the healthcare ecosystem shifts toward personalized and preventative care, GLP-1 analogs are becoming a cornerstone in the future of metabolic disease management. The GLP-1 market experienced notable advancements characterized by expanded indications, new product launches, and intensified competition. Major players like Novo Nordisk and Eli Lilly introduced next-generation formulations with improved dosing convenience, enhancing patient

adherence. These developments were complemented by a surge in prescriptions driven by increased physician confidence and growing consumer interest in weight management solutions. The FDA and EMA granted new approvals for once-weekly and oral GLP-1 drugs, encouraging broader adoption in both diabetes and obesity segments. Clinical studies also highlighted the cardioprotective effects of GLP-1 therapies, positioning them as a preferred option for patients with coexisting cardiovascular conditions. Moreover, pharmaceutical companies entered strategic partnerships to co-develop combination therapies, integrating GLP-1 with other agents such as SGLT2 inhibitors. Digital health platforms began incorporating GLP-1 adherence monitoring tools, reflecting a shift toward data-driven patient management. As reimbursement coverage expanded in key markets, accessibility also improved, driving market penetration further across emerging regions. The GLP-1 market is expected to witness sustained momentum fueled by innovation, patient-centric delivery mechanisms, and increased investment in pipeline development. Companies are focusing on ultra-long-acting formulations and oral peptide technologies to reduce injection frequency and enhance patient comfort. Additionally, combination therapies that pair GLP-1 receptor agonists with agents targeting appetite regulation or insulin sensitivity are projected to gain regulatory approval and market entry. Precision medicine is anticipated to play a larger role, with biomarker-driven approaches guiding patient selection and dosing strategies. Geographically, market growth will accelerate in Latin America and Southeast Asia, aided by healthcare infrastructure development and growing diabetic populations. Public health initiatives to curb obesity will further strengthen demand, particularly as GLP-1 drugs prove effective in weight reduction. Moreover, biosimilar development may enter the landscape, potentially reducing treatment costs and improving accessibility. As Therapeutic applications of GLP-1 analogs continue expanding into areas such as non-alcoholic steatohepatitis (NASH) and polycystic ovary syndrome (PCOS), the market's trajectory remains on a promising path toward broader clinical integration.

Key Insights Glucagon-Like Peptide 1 Market

Pharmaceutical companies are prioritizing oral GLP-1 formulations to reduce reliance on injectables, enhancing patient convenience and boosting compliance among newly diagnosed patients and needle-averse individuals.

GLP-1 receptor agonists are increasingly used for obesity treatment, with clinical trials and real-world results demonstrating significant weight loss, driving broader therapeutic positioning beyond diabetes.

Digital health integration is rising, with telemedicine platforms incorporating GLP-1 adherence support tools and real-time glucose tracking to optimize patient outcomes and engagement.

Strategic collaborations between pharma companies and tech firms are emerging, aimed at developing smart delivery systems and AI-based tools for personalized treatment regimens.

Growing research into GLP-1's role in treating non-diabetic conditions such as NASH and cardiovascular diseases is expanding the drug class's clinical potential and future market scope.

The global rise in Type 2 diabetes and obesity is driving demand for effective and long-term therapeutic solutions like GLP-1 receptor agonists.

Strong clinical outcomes and cardiovascular safety profiles make GLP-1 drugs a preferred choice among physicians for at-risk patient populations.

Improved reimbursement policies and healthcare coverage in both developed and emerging markets are making GLP-1 therapies more accessible.

Ongoing innovation in drug delivery methods, including once-weekly dosing and oral versions, is boosting patient adherence and expanding the user base.

High treatment costs remain a critical challenge, limiting access in low-income populations and placing strain on healthcare systems despite increasing demand and proven clinical efficacy.

Glucagon-Like Peptide 1 Market Segmentation

By Product

Trulicity

Ozempic

Victoza

Rybelsus

Other Types

By Route of Administration

Oral

Parenteral

Other Routes

By End-Users

Hospitals

Specialty Clinics

Other End Users

Key Companies Analysed

Novo Nordisk AS

Sanofi SA

Eli Lilly and Co

AstraZeneca plc

Pfizer Inc

Boehringer Ingelheim International GmbH

F Hoffmann-La Roche Ltd

Bristol-Myers Squibb Company

Baxter

Hikma Pharmaceuticals plc

Zealand Pharma A/S

Intarcia Therapeutics Inc.

GlaxoSmithKline plc

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Shanghai Benemae Pharmaceutical Corporation

Adocia

Biocon

Hanmi Pharmaceutical Co Ltd

Ligand Pharmaceuticals Incorporated

Advinus Therapeutics Ltd

Mitsubishi Tanabe Pharma Corporation

Daiichi Sankyo Company Limited

Sun Pharmaceutical Industries Ltd

Union Chimique Belge

Amylin Pharmaceuticals LLC

Academic Pharmaceuticals Inc

ConjuChem Biotechnologies

MannKind Corporation:

Provention Bio Inc

Regeneron Pharmaceuticals

Glucagon-Like Peptide 1 Market Analytics

The report employs rigorous tools, including Porter's Five Forces, value chain mapping, and scenario-based modeling, to assess supply–demand dynamics. Cross-sector influences from parent, derived, and substitute markets are evaluated to identify risks and opportunities. Trade and pricing analytics provide an up-to-date view of international flows, including leading exporters, importers, and regional price trends.

Macroeconomic indicators, policy frameworks such as carbon pricing and energy security strategies, and evolving consumer behavior are considered in forecasting scenarios. Recent deal flows, partnerships, and technology innovations are incorporated to assess their impact on future market performance.

Glucagon-Like Peptide 1 Market Competitive Intelligence

The competitive landscape is mapped through OG Analysis' proprietary frameworks, profiling leading companies with details on business models, product portfolios, financial performance, and strategic initiatives. Key developments such as mergers & acquisitions, technology collaborations, investment inflows, and regional expansions are analyzed for their competitive impact. The report also identifies emerging players and innovative startups contributing to market disruption.

Regional insights highlight the most promising investment destinations, regulatory landscapes, and evolving partnerships across energy and industrial corridors.

Countries Covered

North America — Glucagon-Like Peptide 1 market data and outlook to 2034

United States

Canada

Mexico

Europe — Glucagon-Like Peptide 1 market data and outlook to 2034

Germany

United Kingdom

France

Italy

Spain

BeNeLux

Russia

Sweden

Asia-Pacific — Glucagon-Like Peptide 1 market data and outlook to 2034

China

Japan

India

South Korea

Australia

Indonesia

Malaysia

Vietnam

Middle East and Africa — Glucagon-Like Peptide 1 market data and outlook to 2034

Saudi Arabia

South Africa

Iran

UAE

Egypt

South and Central America — Glucagon-Like Peptide 1 market data and outlook to 2034

Brazil

Argentina

Chile

Peru

** We can include data and analysis of additional countries on demand.*

Research Methodology

This study combines primary inputs from industry experts across the Glucagon-Like Peptide 1 value chain with secondary data from associations, government publications, trade databases, and company disclosures. Proprietary modeling techniques, including data triangulation, statistical correlation, and scenario planning, are applied to deliver reliable market sizing and forecasting.

Key Questions Addressed

What is the current and forecast market size of the Glucagon-Like Peptide 1

industry at global, regional, and country levels?

Which types, applications, and technologies present the highest growth potential?

How are supply chains adapting to geopolitical and economic shocks?

What role do policy frameworks, trade flows, and sustainability targets play in shaping demand?

Who are the leading players, and how are their strategies evolving in the face of global uncertainty?

Which regional “hotspots” and customer segments will outpace the market, and what go-to-market and partnership models best support entry and expansion?

Where are the most investable opportunities—across technology roadmaps, sustainability-linked innovation, and M&A—and what is the best segment to invest over the next 3–5 years?

Your Key Takeaways from the Glucagon-Like Peptide 1 Market Report

Global Glucagon-Like Peptide 1 market size and growth projections (CAGR), 2024-2034

Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Glucagon-Like Peptide 1 trade, costs, and supply chains

Glucagon-Like Peptide 1 market size, share, and outlook across 5 regions and 27 countries, 2023-2034

Glucagon-Like Peptide 1 market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034

Short- and long-term Glucagon-Like Peptide 1 market trends, drivers, restraints, and opportunities

Porter’s Five Forces analysis, technological developments, and Glucagon-Like

Peptide 1 supply chain analysis

Glucagon-Like Peptide 1 trade analysis, Glucagon-Like Peptide 1 market price analysis, and Glucagon-Like Peptide 1 supply/demand dynamics

Profiles of 5 leading companies—overview, key strategies, financials, and products

Latest Glucagon-Like Peptide 1 market news and developments

Additional Support

With the purchase of this report, you will receive

An updated PDF report and an MS Excel data workbook containing all market tables and figures for easy analysis.

7-day post-sale analyst support for clarifications and in-scope supplementary data, ensuring the deliverable aligns precisely with your requirements.

Complimentary report update to incorporate the latest available data and the impact of recent market developments.

** The updated report will be delivered within 3 working days*

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL GLUCAGON-LIKE PEPTIDE 1 MARKET SUMMARY, 2025

- 2.1 Glucagon-Like Peptide 1 Industry Overview
 - 2.1.1 Global Glucagon-Like Peptide 1 Market Revenues (In US\$ billion)
- 2.2 Glucagon-Like Peptide 1 Market Scope
- 2.3 Research Methodology

3. GLUCAGON-LIKE PEPTIDE 1 MARKET INSIGHTS, 2024-2034

- 3.1 Glucagon-Like Peptide 1 Market Drivers
- 3.2 Glucagon-Like Peptide 1 Market Restraints
- 3.3 Glucagon-Like Peptide 1 Market Opportunities
- 3.4 Glucagon-Like Peptide 1 Market Challenges
- 3.5 Tariff Impact on Global Glucagon-Like Peptide 1 Supply Chain Patterns

4. GLUCAGON-LIKE PEPTIDE 1 MARKET ANALYTICS

- 4.1 Glucagon-Like Peptide 1 Market Size and Share, Key Products, 2025 Vs 2034
- 4.2 Glucagon-Like Peptide 1 Market Size and Share, Dominant Applications, 2025 Vs 2034
- 4.3 Glucagon-Like Peptide 1 Market Size and Share, Leading End Uses, 2025 Vs 2034
- 4.4 Glucagon-Like Peptide 1 Market Size and Share, High Growth Countries, 2025 Vs 2034
- 4.5 Five Forces Analysis for Global Glucagon-Like Peptide 1 Market
 - 4.5.1 Glucagon-Like Peptide 1 Industry Attractiveness Index, 2025
 - 4.5.2 Glucagon-Like Peptide 1 Supplier Intelligence
 - 4.5.3 Glucagon-Like Peptide 1 Buyer Intelligence
 - 4.5.4 Glucagon-Like Peptide 1 Competition Intelligence
 - 4.5.5 Glucagon-Like Peptide 1 Product Alternatives and Substitutes Intelligence
 - 4.5.6 Glucagon-Like Peptide 1 Market Entry Intelligence

5. GLOBAL GLUCAGON-LIKE PEPTIDE 1 MARKET STATISTICS – INDUSTRY

Glucagon-Like Peptide 1 Market Outlook 2025-2034: Market Share, and Growth Analysis By Product (Trulicity, Oze...

REVENUE, MARKET SHARE, GROWTH TRENDS AND FORECAST BY SEGMENTS, TO 2034

5.1 World Glucagon-Like Peptide 1 Market Size, Potential and Growth Outlook, 2024-2034 (\$ billion)

5.1 Global Glucagon-Like Peptide 1 Sales Outlook and CAGR Growth By Product, 2024- 2034 (\$ billion)

5.2 Global Glucagon-Like Peptide 1 Sales Outlook and CAGR Growth By Route of Administration, 2024- 2034 (\$ billion)

5.3 Global Glucagon-Like Peptide 1 Sales Outlook and CAGR Growth By End-Users, 2024- 2034 (\$ billion)

5.4 Global Glucagon-Like Peptide 1 Market Sales Outlook and Growth by Region, 2024-2034 (\$ billion)

6. ASIA PACIFIC GLUCAGON-LIKE PEPTIDE 1 INDUSTRY STATISTICS – MARKET SIZE, SHARE, COMPETITION AND OUTLOOK

6.1 Asia Pacific Glucagon-Like Peptide 1 Market Insights, 2025

6.2 Asia Pacific Glucagon-Like Peptide 1 Market Revenue Forecast By Product, 2024-2034 (USD billion)

6.3 Asia Pacific Glucagon-Like Peptide 1 Market Revenue Forecast By Route of Administration, 2024- 2034 (USD billion)

6.4 Asia Pacific Glucagon-Like Peptide 1 Market Revenue Forecast By End-Users, 2024- 2034 (USD billion)

6.5 Asia Pacific Glucagon-Like Peptide 1 Market Revenue Forecast by Country, 2024-2034 (USD billion)

6.5.1 China Glucagon-Like Peptide 1 Market Size, Opportunities, Growth 2024- 2034

6.5.2 India Glucagon-Like Peptide 1 Market Size, Opportunities, Growth 2024- 2034

6.5.3 Japan Glucagon-Like Peptide 1 Market Size, Opportunities, Growth 2024- 2034

6.5.4 Australia Glucagon-Like Peptide 1 Market Size, Opportunities, Growth 2024-2034

7. EUROPE GLUCAGON-LIKE PEPTIDE 1 MARKET DATA, PENETRATION, AND BUSINESS PROSPECTS TO 2034

7.1 Europe Glucagon-Like Peptide 1 Market Key Findings, 2025

7.2 Europe Glucagon-Like Peptide 1 Market Size and Percentage Breakdown By Product, 2024- 2034 (USD billion)

7.3 Europe Glucagon-Like Peptide 1 Market Size and Percentage Breakdown By Route

of Administration, 2024- 2034 (USD billion)

7.4 Europe Glucagon-Like Peptide 1 Market Size and Percentage Breakdown By End-Users, 2024- 2034 (USD billion)

7.5 Europe Glucagon-Like Peptide 1 Market Size and Percentage Breakdown by Country, 2024- 2034 (USD billion)

7.5.1 Germany Glucagon-Like Peptide 1 Market Size, Trends, Growth Outlook to 2034

7.5.2 United Kingdom Glucagon-Like Peptide 1 Market Size, Trends, Growth Outlook to 2034

7.5.2 France Glucagon-Like Peptide 1 Market Size, Trends, Growth Outlook to 2034

7.5.2 Italy Glucagon-Like Peptide 1 Market Size, Trends, Growth Outlook to 2034

7.5.2 Spain Glucagon-Like Peptide 1 Market Size, Trends, Growth Outlook to 2034

8. NORTH AMERICA GLUCAGON-LIKE PEPTIDE 1 MARKET SIZE, GROWTH TRENDS, AND FUTURE PROSPECTS TO 2034

8.1 North America Snapshot, 2025

8.2 North America Glucagon-Like Peptide 1 Market Analysis and Outlook By Product, 2024- 2034 (\$ billion)

8.3 North America Glucagon-Like Peptide 1 Market Analysis and Outlook By Route of Administration, 2024- 2034 (\$ billion)

8.4 North America Glucagon-Like Peptide 1 Market Analysis and Outlook By End-Users, 2024- 2034 (\$ billion)

8.5 North America Glucagon-Like Peptide 1 Market Analysis and Outlook by Country, 2024- 2034 (\$ billion)

8.5.1 United States Glucagon-Like Peptide 1 Market Size, Share, Growth Trends and Forecast, 2024- 2034

8.5.1 Canada Glucagon-Like Peptide 1 Market Size, Share, Growth Trends and Forecast, 2024- 2034

8.5.1 Mexico Glucagon-Like Peptide 1 Market Size, Share, Growth Trends and Forecast, 2024- 2034

9. SOUTH AND CENTRAL AMERICA GLUCAGON-LIKE PEPTIDE 1 MARKET DRIVERS, CHALLENGES, AND FUTURE PROSPECTS

9.1 Latin America Glucagon-Like Peptide 1 Market Data, 2025

9.2 Latin America Glucagon-Like Peptide 1 Market Future By Product, 2024- 2034 (\$ billion)

9.3 Latin America Glucagon-Like Peptide 1 Market Future By Route of Administration, 2024- 2034 (\$ billion)

9.4 Latin America Glucagon-Like Peptide 1 Market Future By End-Users, 2024- 2034 (\$ billion)

9.5 Latin America Glucagon-Like Peptide 1 Market Future by Country, 2024- 2034 (\$ billion)

9.5.1 Brazil Glucagon-Like Peptide 1 Market Size, Share and Opportunities to 2034

9.5.2 Argentina Glucagon-Like Peptide 1 Market Size, Share and Opportunities to 2034

10. MIDDLE EAST AFRICA GLUCAGON-LIKE PEPTIDE 1 MARKET OUTLOOK AND GROWTH PROSPECTS

10.1 Middle East Africa Overview, 2025

10.2 Middle East Africa Glucagon-Like Peptide 1 Market Statistics By Product, 2024-2034 (USD billion)

10.3 Middle East Africa Glucagon-Like Peptide 1 Market Statistics By Route of Administration, 2024- 2034 (USD billion)

10.4 Middle East Africa Glucagon-Like Peptide 1 Market Statistics By End-Users, 2024-2034 (USD billion)

10.5 Middle East Africa Glucagon-Like Peptide 1 Market Statistics by Country, 2024-2034 (USD billion)

10.5.1 Middle East Glucagon-Like Peptide 1 Market Value, Trends, Growth Forecasts to 2034

10.5.2 Africa Glucagon-Like Peptide 1 Market Value, Trends, Growth Forecasts to 2034

11. GLUCAGON-LIKE PEPTIDE 1 MARKET STRUCTURE AND COMPETITIVE LANDSCAPE

11.1 Key Companies in Glucagon-Like Peptide 1 Industry

11.2 Glucagon-Like Peptide 1 Business Overview

11.3 Glucagon-Like Peptide 1 Product Portfolio Analysis

11.4 Financial Analysis

11.5 SWOT Analysis

12 APPENDIX

12.1 Global Glucagon-Like Peptide 1 Market Volume (Tons)

12.1 Global Glucagon-Like Peptide 1 Trade and Price Analysis

12.2 Glucagon-Like Peptide 1 Parent Market and Other Relevant Analysis

12.3 Publisher Expertise

12.2 Glucagon-Like Peptide 1 Industry Report Sources and Methodology

I would like to order

Product name: Glucagon-Like Peptide 1 Market Outlook 2025-2034: Market Share, and Growth Analysis
By Product (Trulicity, Ozempic, Victoza, Rybelsus, Other Types), By Route of
Administration (Oral, Parenteral, Other Routes), By End-Users

Product link: <https://marketpublishers.com/r/GB8B963FC5F5EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/GB8B963FC5F5EN.html>